Free Trial
NASDAQ:OBSV

ObsEva (OBSV) Stock Price, News & Analysis

ObsEva logo

About ObsEva Stock (NASDAQ:OBSV)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
255 shs
Average Volume
8.94 million shs
Market Capitalization
$7.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

OBSV Stock News Headlines

ObsEva (NASDAQ:OBSV) Research Coverage Started at StockNews.com
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
ObsEva Announces Update on Board of Directors
ObsEva SA OBSN
ObsEva SA OBSEF
See More Headlines

OBSV Stock Analysis - Frequently Asked Questions

ObsEva SA (NASDAQ:OBSV) issued its earnings results on Thursday, November, 4th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.23.

ObsEva (OBSV) raised $98 million in an initial public offering on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ObsEva investors own include NIO (NIO), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Allena Pharmaceuticals (ALNA), Bionano Genomics (BNGO) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
11/04/2021
Today
4/20/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OBSV
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-58,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$20.11 million
Price / Cash Flow
N/A
Book Value
$0.41 per share
Price / Book
N/A

Miscellaneous

Free Float
66,743,000
Market Cap
$7.94 million
Optionable
Not Optionable
Beta
0.68

Social Links

10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:OBSV) was last updated on 4/21/2025 by MarketBeat.com Staff
From Our Partners